Customer problem: In 80% of the cases babies present with only three symptoms, which have more than 160 possible diagnoses. On average each baby receives 9 single gene test serially before a correct diagnosis is made. Physicians want a faster test that can also detect new mutations. Hospital administrators and payors want to control the most expensive part of their cost.
Product/Services: We provide The NewbornDx Test™ that would reduce the diagnosis of 350 different genetic disorders to 2 days and reduce hospital stays by 40%. We use a novel non-invasive DNA extraction method on dried blood spots coupled with our proprietary LifeTime Database™ of rare variants to detect new mutations others would miss.
Target market: The beachhead for our test are the 450,000 symptomatic neonates in NICUs and the 900,000 pediatric cases in Children’s Hospitals in the US. With an average selling price of $2,500 and $2,000 the potential addressable markets are $1.1B and $1.8B, respectively.